DE69939819D1 - Verfahren zur krebsdiagnose mittels eines chimärischen toxin - Google Patents

Verfahren zur krebsdiagnose mittels eines chimärischen toxin

Info

Publication number
DE69939819D1
DE69939819D1 DE69939819T DE69939819T DE69939819D1 DE 69939819 D1 DE69939819 D1 DE 69939819D1 DE 69939819 T DE69939819 T DE 69939819T DE 69939819 T DE69939819 T DE 69939819T DE 69939819 D1 DE69939819 D1 DE 69939819D1
Authority
DE
Germany
Prior art keywords
chimeric toxin
cancer diagnosis
gnrh
relates
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69939819T
Other languages
English (en)
Inventor
Haya Lorberboum-Galski
Ami Ben-Yehudah
Amotz Nechushtan
Shai Yarkoni
Irina Marianovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE69939819D1 publication Critical patent/DE69939819D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69939819T 1998-03-24 1999-03-24 Verfahren zur krebsdiagnose mittels eines chimärischen toxin Expired - Fee Related DE69939819D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/046,992 US6140066A (en) 1998-03-24 1998-03-24 Methods of cancer diagnosis using a chimeric toxin
PCT/IL1999/000166 WO1999049059A2 (en) 1998-03-24 1999-03-24 Methods of cancer diagnosis using a chimeric toxin

Publications (1)

Publication Number Publication Date
DE69939819D1 true DE69939819D1 (de) 2008-12-11

Family

ID=21946472

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939819T Expired - Fee Related DE69939819D1 (de) 1998-03-24 1999-03-24 Verfahren zur krebsdiagnose mittels eines chimärischen toxin

Country Status (10)

Country Link
US (1) US6140066A (de)
EP (1) EP1066390B1 (de)
CN (1) CN1303438A (de)
AT (1) ATE412756T1 (de)
AU (1) AU758839B2 (de)
CA (1) CA2323786A1 (de)
DE (1) DE69939819D1 (de)
IL (1) IL138655A0 (de)
NZ (1) NZ507294A (de)
WO (1) WO1999049059A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma
US8962558B2 (en) 1997-07-04 2015-02-24 Johannes C. van Groeninghen Methods for reducing GnRH-positive tumor cell proliferation using the GnRH antagonist IN3
DE19728737C1 (de) * 1997-07-04 1999-02-11 Johannes Christian Groeninghen Verfahren zur Erkennung und Bestimmung von GnRH-Rezeptoren und die Verwendung von GnRH-Agonisten und GnRH-Antagonisten zur Behandlung eines Tumors ausgehend vom Hirn und/oder Nervensystem und/oder den Hirnhäuten
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
JP2001510683A (ja) * 1997-07-11 2001-08-07 ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｐｓｅｕｄｏｍｏｎａｓ体外毒素Ａ様キメラ免疫原
US6645490B2 (en) * 1998-03-02 2003-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1555268B (zh) * 2001-07-17 2013-04-03 研究发展基金会 含促调亡蛋白质的治疗剂
CA2488858A1 (en) * 2002-06-12 2003-12-24 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
CN1683416A (zh) * 2004-04-13 2005-10-19 李相哲 高效低毒的系列功能蛋白
CN100379869C (zh) * 2004-08-09 2008-04-09 生宝生物科技股份有限公司 超抗原融合蛋白及其应用方法
CN1768862A (zh) * 2004-10-26 2006-05-10 北京诺思兰德生物技术有限责任公司 一类能与表达GnRH受体的癌细胞特异结合且用锝－99m标记的蛋白
US20060171919A1 (en) * 2005-02-01 2006-08-03 Research Development Foundation Targeted polypeptides
KR100808735B1 (ko) 2006-11-04 2008-02-28 진은철 황체호르몬 분비호르몬 및 독소분자의 복합체를유효성분으로 하는 건선 예방 및 치료제
CN101195822B (zh) * 2006-12-08 2012-08-08 湖南康都制药有限公司 高亲和性靶向融合蛋白
CN101343328B (zh) * 2008-08-25 2011-06-01 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质
CN103864938A (zh) * 2014-03-24 2014-06-18 北京博翱泰生物技术有限公司 靶特异性双突变体融合蛋白质及其制备工艺
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1239892A (en) * 1991-01-04 1992-08-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The A method for constructing antigens
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
IL118570A (en) * 1996-06-04 2007-06-17 Shai Yarkoni Use of a chimeric protein that includes Met – GnRH in the preparation of a pharmaceutical preparation for the treatment of adenocarcinoma or patocarcinoma

Also Published As

Publication number Publication date
WO1999049059A3 (en) 1999-12-02
US6140066A (en) 2000-10-31
WO1999049059A2 (en) 1999-09-30
IL138655A0 (en) 2001-10-31
CN1303438A (zh) 2001-07-11
EP1066390A2 (de) 2001-01-10
AU758839B2 (en) 2003-04-03
EP1066390B1 (de) 2008-10-29
NZ507294A (en) 2003-05-30
AU2955199A (en) 1999-10-18
ATE412756T1 (de) 2008-11-15
CA2323786A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
DE69939819D1 (de) Verfahren zur krebsdiagnose mittels eines chimärischen toxin
PE20050712A1 (es) Anticuerpos rg1
ZA202100390B (en) Fusion constructs and methods of using thereof
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
IL126314A0 (en) Monoclonal specific antibodies
EP2502937A3 (de) Anti-CD 79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
ECSP024210A (es) Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas
ATE303161T1 (de) Humanisierung von anti-carcinoembryonalen antigen anti-idiotypischen antikörper und dessen verwendung als tumorvakzin und zur markierung
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
EP1064303A4 (de) Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
EA200800094A1 (ru) Антитела cd19 и их использование
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MXPA05008794A (es) Antigeno de glicoproteina sima135 expresado en celulas tumorales humanas metastasicas.
ATE526037T1 (de) Verfahren zum abtöten von tumorzellen mittels targeting von auf apoptotischen tumorzellen exponierten internen antigenen
ATE500276T1 (de) Humanisierte col-1-antikörper mit substituierten resten am gerüst, und deren anwendung
MXPA04003508A (es) Anticuerpos humanos que se unen a mn.
MX2022002524A (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer.
WO2021056025A3 (en) Anti-epha10 antibodies and methods of use thereof
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE69829001D1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
UY26170A1 (es) Antigeno (c42) asociados a tumores
MX2021008453A (es) Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee